Dalio's gift is right here....3 million
A major gift of $3 million from an anonymous donor funded the establishment of the research center. A second major gift, from Stony Brook University alumni Eugene and Carol Cheng, purchased an EECP (Enhanced External Counter-Pulsation) device for the new research center. The center will study EECP – which uses cuff-like devices on the legs to increase blood flow to the heart by squeezing in sequence with the patient’s heartbeat – as a way to enhance the blood flow to the heart by developing collateral blood vessels and enhancing coronary blood flow and reserves - :
You wont have to wait 3 years. We have all waited Long enough here. Trial will have 1000's of patients and tests many endpoints. We should see many results over those 3 years.
Heres another questions for potential buyers of vaso. Right now I have a dozen little bio's with great IP but little cash to get them advanced to the next trial stage. The holy grail for each is to get a partnership with
big pharma. Most of these deals have pharma paying for trial in exchange for large % of future revs. Little bio
may get some small milestone payments along the way, but they give up much in the back end. These type of deals give instant cred to little bio and stock price immediately advances.
With the Dalio sponsorship, we have a deep pocketed, (individually bigger than some pharma's) entity that
is paying for all trial expenses for 3 years and taking NOTHING of the future rev stream that successful trials may produce. I don't know of any sweeter deal than that.
So, trade for pennys, or look for the change that Dalio is famous for finding; the macro one.
Smalls, you really seem to miss the point here. Of course he didn't talk about the return in monetary terms. The guy has billions, he is not here for the money. And there simply in "no expectation" priced into stock is a
great thing for those of us who know how story is evolving. Article hasn't generated interest here because nobody on the street has connected the dots yet. And this isn't even about an uptick in short term sales due to stonybrook. That is short sited at best.
What we are looking at here is that sea change. Real trials that are sponsored by someone who doesn't throw money around without much DD. For me, trials have always been the missing leg of legitimacy. This news will be bigger than the GE deal to the future of vaso. IMHO
Good Luck longs
You have to ask yourself why the 31st richest person in USA and the man who runs the largest hedge fund in the world, would have anything to do with the technology of little vaso. This relationship is, right now, way under the radar, and no doubt wanted to be that way by Dalio. But, much less credible associations than this have create buying panics in little companys stocks. Readers here are fortunate to have a heads up.
So, we have a stock under 30 cents, with a company that has over 10 million in cash, is buying back stock in the open market, and says it will be profitable this year, has a partnership with one of the oldest and largest industrial companys in America-GE, and now has trials payed for by the man who runs a 130 Billion dollar
hedge fund. Just your everyday, run of the mill, speculative penny stock I guess.........................
This guy is the real deal and has gotten a lot of press recently for a video he made and posted on web entitled " How The Economy Works." He was on cnbc last week talking about video, but I had never connected him with vaso. I can only guess he might have tried eecp or know someone who has. These trials
he is paying for will be the basis for increased insurance coverage and increased indications beyond refractory angina. This is even better than company sponsored trial as we have no cost and it is being done over a 3 year period(sure we will see results published over those years), and it is being done by a very credible doc and hospital in THE USA. There is no way CMS or FDA will be able to ignore these results.
Healthcare is changing and vaso may just yet be a big part of it. One thing is for sure, acceptance is always
trial related and NOW we have a legitimate trail based here and sponsored by very deep pockets.
Research at the center is also being supported by several recent philanthropic gifts that were matched by the Simons Foundation Challenge Grant. One major gift, from Stony Brook University alumni Eugene and Carol Cheng, established the Carol and Eugene Cheng Cardiovascular Imaging Research Endowment. Funds from the gift were used to purchase the EECP machine. Another major gift of $750,000, from Charles A. Gargano, former U.S. Ambassador to Trinidad and Tobago, is being used to establish the Ambassador Charles Gargano Chair and professorship in Advanced Cardiovascular Imaging at Stony Brook University School of Medicine.
The research being conducted at the center could ultimately benefit not only patients with or at risk of developing coronary artery disease, say Dr. Poon, but also heart failure and Alzheimer’s disease patients, as the results are translated into new approaches to patient care. Thousands of patients will benefit from receiving EECP as an FDA approved treatment during the course of research exploring alternative uses for the therapy. Additional exploratory research will examine use of EECP in preventing muscle soreness and injury in elite athletes
"My only concern is how much more dilution did the company agree to in order to bring R.D. on board?"
This guys advocacy is not for sale. He cant and would not receive any shares from company for this "charity"
work. This has absolutely nothing in common with RIOS. He is well connected. And, watch out shorts if he ever wanted to get vaso national exposure...........
The possibilities here are endless and all positive. I didn't give this announcement the attention it deserved. Thanks johndoe
What you said about the end of the buyback is just wrong. Size on bid is company and was in effect today. That is a fact smoke2much. And as far as your trading vaso, I wish I had a nickel for every yahoo board "genius" who extolls his great trading virtues. Good for you, buying low and selling high; all the time. Super.
Don't remember you posting during that accumulation phase at a nickel, but I am sure you were a buyer. Smalls and I were the only ones I remember back then, but if you say it it must be true.
You are an idiot. You have no clue as to what has been spent on buyback so your statement has zero
merit. Do a little DD before you post. Or better yet, don't post at all.
Company buyback still in force and trading range remains intact. Its also very possible buyback will
be added to. That would be the 3rd extension. So, shorty, if you are hoping for an end to buyback, be careful
as company has plenty of cash to add to current buyback number.
32k shorted. I would bet that opening tick of 12,000 shares at .2203 was short trying to start a real selloff-bear attack. (No long would be stupid enough to sell there with the buyback in place) We see many gap lower opening ticks of 100 shares over the years, but none with that size. So, short failed to cause a real slide, so now what, especially after todays bullish outside day. We shall see
A real battle to keep vaso under .3. Short #'s will tell the tale tonight.
We need to break above .3 and today is setting up as a bullish outside day. We have had few of those here(have to go way back) and given the decent volume and that 10,000+ tick low to open at .2203, it may just be the signal of a soon to be 3 handle. These are usually very good signals, so if we close above .28; its on.
We shall see. What are you going to do about it shorty???????
Hey sno, we all are aware of pecking order of securities in BK. So, the basis of the conspiracy theory is that note holders will make out on liquidation while we will not. Now, knowing that Italians were part of this last note, do you really think liquidation value(IP) will be worth anywhere near the cost basis(forget profit) of their investment over the years?? And owning it means nothing, HK company already has rights. They want company to survive and will only make if this company survives. This is aligned with shareholders.
No doubt, a convoluted mess. I choose incompetence, or some type of delusions of grandeur by Fink when
he was negotiating for deals over the years.
Most if not all bio's who have failed shareholders for so long would have gone BK. I have seen many. RGRX is unique in that it hangs on with a ceo taking in 50 bucks an hour and other insiders loaning company money. You maintain this is all done to steal company from current shareholders on the cheap. I disagree. So, lets see how it ends. I see an end game higher than 6 cents; maybe much higher. If you don't and wish to continue bashing away at the obvious problems here; have at it. But, I certainly wouldn't hold any stock here if I had your opinion.
Check of sngx;(big contract today) huge winner since Kirk got on board. ANd another little bio owned by Italians at one time that was given up for dead after RS, but now rewards shareholders. Lots of donks on that board at one time, not so many now.
Fitz, I have to say, who really cares?? Shareholders should be sick and tired of management wasting money on these booths. Where have they gotten us? All that money over the years traveling worldwide would have been better spent on a company sponsored real protocol FDA trial. We could have done one with the money spent on china acquisition years ago and have had results by now. Ma's strategy is flawed and he is WASTING GEHC deal. So much potential, but we need a visionary. And it aint MA
it happens all the time. Your words. You must have many examples. So.....lets hear them
Ok, pointdexter, give me an example. No platitudes, a real company that purposely held back positive info to keep stock price depressed, while issuing senior securities to themselves to shaft the common shareholders.
You john, are so full of sh+t.
And there are many "significant positive events" that could be pending. Do some real DD or shout the F up.
If these notes don't get converted to shares; investors in those notes lose. Its that simple. To say that they are positioning for BK and they will be winners in such case in nonsense. There will be little to no value in BK and you get bet the Italians (given their cost basis) will be the biggest losers.
Coverts are buying time. The constant delay is not the best case scenario and dilution aint great, but shareholders still have great upside. Note buyers are not going to risk their reputations and possible sec scrutiny lending these small sums. Conspiracies are a dime a dozen on this silly venue.
If nite is big short, they are in trouble. They were looking at BK by now. And who could blame them. These
type of short term extensions by people in the know is unprecedented.